Dr. Agalwal’s healthcare LTD., one of the major Indian eye care service providers, will launch a 3,027.3 rupee recruitment on January 29.
According to Red Herring’s prospectus, the proposed IPO consists of a 300 rupee fresh issue and a 2,727.3 rupee sales component.
Do I need to subscribe to the public problem? What a securities company recommends:
AXIS Capital emphasized the status of Dr. Agalwar as the largest eye care chain in India, which leads 25 % market share in FY2024.
Securities companies believe that consumers’ trust in the brand, the proven abilities to integrate the acquisition, and the consistent growth of operating margins will provide promising opportunities for long -term investors.
However, AXIS pointed out that there are competitors in this segment, such as ASG Hospital and Eye-Q Vision, such as APOLLO HOSPITALS and FORTIS HEALTHCARE. These players say that market share is getting smaller, but it can cause issues.
SBI SECURITIES reported that Dr. Agarwal set it in 33.9 times based on a multiple of EV/EBITDA in the fiscal year ending in March 2024 and 27.7 times in the first half of the ongoing accounting fiscal year. I mentioned in the book.
Interest, tax, depreciation, and the ratio of corporate value and revenue before depreciation can help investors evaluate whether corporate evaluation is more appropriate than revenue. If the ratio is low, a considerable amount is indicated, but a higher ratio may suggest an excessive price setting.
The advantages owned by Icare Providers include a comprehensive service, a powerful clinical governance, a market capitalization of 9.5 times, and a sales ratio, according to securities companies. On the other hand, the risks include a high turnover rate, including regional concentration and regulation issues.
SBI Securities emphasized the company’s operation efficiency and a robust extension strategy. The hub and spokes model has a large amount of patients with a minimum pre -payment investment, which is an advantage according to the memo.
Securities companies recommend that the IPO prices are consistent with similar companies, and that investors subscribe at cut -off prices for long -term investments.
Anand Rathi emphasized the company’s evaluation at 134 times the profit per share of the 2024 fiscal year. He has acknowledged Dr. Agarwal’s 25 % market share and eye care sector leadership. Relying on the company’s computing material agreement and geographical concentration with our doctors has been flagged as a potential risk.
Despite the abundant prices, securities companies have issued a “subscription -long -term” rating and issued banks on future growth.
